PRKCE: A Potential Drug Target and Biomarker for PRKCE-related Diseases

Target Name: PRKCE

NCBI ID: G5581

PRKCE

PRKCE: A Potential Drug Target and Biomarker for PRKCE-related Diseases

Progeria rays are a group of inherited diseases characterized by the rapid aging process and the development of age-related diseases. These diseases can affect various organs and systems in the body, including the skin, heart, lungs, and brain. PRKCE (nPKC-epsilon) is a protein that has been identified as a potential drug target or biomarker for PRKCE-related diseases. In this article, we will discuss the biology of PRKCE, its potential as a drug target, and its potential utility as a biomarker for the diagnosis and treatment of PRKCE-related diseases.

Biochemistry and gene function

PRKCE is a 21-kDa protein that is expressed in various tissues and organs, including skin, heart, lungs, liver, and brain. It is a member of the nucleotide-binding protein (NBP) family and is characterized by the presence of a nucleotide-binding domain (NBD) and a leucine-rich repeat (LRR) domain. The NBD is responsible for the protein's nuclear localization, while the LRR domain is involved in protein-protein interactions and modulation of protein stability.

PRKCE is involved in various cellular processes, including cell signaling, DNA replication, and apoptosis. It has been shown to play a role in the regulation of cell cycle progression, cell survival, and inflammation. PRKCE has also been shown to be involved in the development of age-related diseases, including PRKCE-related diseases.

Potential drug target

PRKCE has been identified as a potential drug target for PRKCE-related diseases due to its involvement in various cellular processes that are associated with the development of these diseases. One of the main mechanisms by which PRKCE contributes to the development of PRKCE-related diseases is its role in the regulation of cell cycle progression. PRKCE has been shown to play a role in the regulation of cell cycle entry, which is critical for the development and progression of cancer.

In addition to its role in cell cycle regulation, PRKCE has also been shown to contribute to the development of age-related diseases. As discussed above, PRKCE is involved in the regulation of DNA replication and has been shown to play a role in the development of age-related diseases. Additionally, PRKCE has also been shown to be involved in the regulation of apoptosis, which is a critical mechanism that regulates cell death and has a role in the development of age-related diseases.

Potential biomarker

PRKCE has also been identified as a potential biomarker for the diagnosis and treatment of PRKCE-related diseases. This is because its levels are often decreased in tissues and organs affected by PRKCE-related diseases, which could be used as a diagnostic or therapeutic target. For example, studies have shown that PRKCE levels are often decreased in the skin, heart, and lungs of individuals with PRKCE-related diseases, which could be used as potential biomarkers for the diagnosis of these diseases.

In addition to its potential as a drug target, PRKCE has also been shown to have potential as a biomarker for the diagnosis of PRKCE-related diseases. Studies have shown that PRKCE levels are often decreased in the blood of individuals with PRKCE-related diseases, which could be used as a potential biomarker for the diagnosis of these diseases.

Conclusion

PRKCE is a protein that has been identified as a potential drug target or biomarker for PRKCE-related diseases. Its involvement in various cellular processes, including cell signaling, DNA replication, and apoptosis, makes it a promising target for the development of new therapies for PRKCE-related diseases. Additionally, its potential as a biomarker for the diagnosis and treatment of these diseases makes it an attractive tool for the development of new diagnostic tests and therapies. Further research is needed to fully understand the role of PRKCE in PRKCE-related diseases and to develop effective treatments.

Protein Name: Protein Kinase C Epsilon

Functions: Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays essential roles in the regulation of multiple cellular processes linked to cytoskeletal proteins, such as cell adhesion, motility, migration and cell cycle, functions in neuron growth and ion channel regulation, and is involved in immune response, cancer cell invasion and regulation of apoptosis. Mediates cell adhesion to the extracellular matrix via integrin-dependent signaling, by mediating angiotensin-2-induced activation of integrin beta-1 (ITGB1) in cardiac fibroblasts. Phosphorylates MARCKS, which phosphorylates and activates PTK2/FAK, leading to the spread of cardiomyocytes. Involved in the control of the directional transport of ITGB1 in mesenchymal cells by phosphorylating vimentin (VIM), an intermediate filament (IF) protein. In epithelial cells, associates with and phosphorylates keratin-8 (KRT8), which induces targeting of desmoplakin at desmosomes and regulates cell-cell contact. Phosphorylates IQGAP1, which binds to CDC42, mediating epithelial cell-cell detachment prior to migration. In HeLa cells, contributes to hepatocyte growth factor (HGF)-induced cell migration, and in human corneal epithelial cells, plays a critical role in wound healing after activation by HGF. During cytokinesis, forms a complex with YWHAB, which is crucial for daughter cell separation, and facilitates abscission by a mechanism which may implicate the regulation of RHOA. In cardiac myocytes, regulates myofilament function and excitation coupling at the Z-lines, where it is indirectly associated with F-actin via interaction with COPB1. During endothelin-induced cardiomyocyte hypertrophy, mediates activation of PTK2/FAK, which is critical for cardiomyocyte survival and regulation of sarcomere length. Plays a role in the pathogenesis of dilated cardiomyopathy via persistent phosphorylation of troponin I (TNNI3). Involved in nerve growth factor (NFG)-induced neurite outgrowth and neuron morphological change independently of its kinase activity, by inhibition of RHOA pathway, activation of CDC42 and cytoskeletal rearrangement. May be involved in presynaptic facilitation by mediating phorbol ester-induced synaptic potentiation. Phosphorylates gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2), which reduces the response of GABA receptors to ethanol and benzodiazepines and may mediate acute tolerance to the intoxicating effects of ethanol. Upon PMA treatment, phosphorylates the capsaicin- and heat-activated cation channel TRPV1, which is required for bradykinin-induced sensitization of the heat response in nociceptive neurons. Is able to form a complex with PDLIM5 and N-type calcium channel, and may enhance channel activities and potentiates fast synaptic transmission by phosphorylating the pore-forming alpha subunit CACNA1B (CaV2.2). In prostate cancer cells, interacts with and phosphorylates STAT3, which increases DNA-binding and transcriptional activity of STAT3 and seems to be essential for prostate cancer cell invasion. Downstream of TLR4, plays an important role in the lipopolysaccharide (LPS)-induced immune response by phosphorylating and activating TICAM2/TRAM, which in turn activates the transcription factor IRF3 and subsequent cytokines production. In differentiating erythroid progenitors, is regulated by EPO and controls the protection against the TNFSF10/TRAIL-mediated apoptosis, via BCL2. May be involved in the regulation of the insulin-induced phosphorylation and activation of AKT1. Phosphorylates NLRP5/MATER and may thereby modulate AKT pathway activation in cumulus cells (PubMed:19542546)

The "PRKCE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRKCE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets